Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 14;13(3):227-237.
doi: 10.1159/000533991. eCollection 2024 Jun.

Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis

Andrea Pasta  1   2 , Francesco Calabrese  1   2 , Ariel Jaffe  3   4 , Sara Labanca  1   2 , Simona Marenco  1   2 , Giulia Pieri  1   2 , Maria Corina Plaz Torres  1   2 , Mario Strazzabosco  3   4 , Edoardo G Giannini  1   2   3
Affiliations

Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis

Andrea Pasta et al. Liver Cancer. .

Abstract

Background: Safety and outcome of atezolizumab/bevacizumab in Child-Pugh B patients with hepatocellular carcinoma (HCC) have not been completely characterized.

Objectives: In this study, we aimed at addressing safety and efficacy of atezolizumab/bevacizumab in Child-Pugh B patients by reviewing the available data and analyzing them by meta-analysis.

Methods: We compared the safety and efficacy of atezolizumab/becavizumab treatment in patients with unresectable HCC and various degrees of liver dysfunction. A total of 8 retrospective, non-randomized, cohort studies were included in this meta-analysis, for a total of 1,071 Child-Pugh A and 225 Child-Pugh B patients. The albumin-bilirubin (ALBI) grade was also used to assess liver function, when available.

Results: Grade ≥3 adverse events were observed in 11.8% of Child-Pugh class A and 26.8% class B patients (p = 0.0001), with an odds ratio (OR) of 0.43 (confidence interval [CI] 0.21-0.90; p = 0.02). Progression-free survival (PFS) at both 6 months (4.90 ± 2.08 vs. 4.75 ± 2.08 months; p = 0.0004) and 12 months (8.83 ± 2.32 vs. 7.26 ± 2.33 months; p = 0.002) was lower in Child-Pugh class B patients. A trend toward a higher objective response rate (ORR) was observed in Child-Pugh class A patients (219/856, 25.6%) as compared to Child-Pugh class B patients (25/138, 18.1%; p = 0.070), while the probability of obtaining an ORR was significantly greater in Child-Pugh A patients (OR 1.79, CI 1.12-2.86; p = 0.02). Median overall survival (OS) was 16.8 ± 2.0 and 6.8 ± 3.2 months in Child-Pugh A and B patients, respectively (mean difference 9.06 months, CI 7.01-11.1, p < 0.0001). Lastly, OS was longer in patients with ALBI grades 1-2 than in those with grade 3 (8.3 ± 11.4 vs. 3.3 ± 5.0 months, p = 0.0008).

Conclusions: Oncological efficacy of atezolizumab/bevacizumab is moderate in Child-Pugh class B patients, and the shorter PFS and OS associated with the greater likelihood of experiencing treatment-related adverse events observed in these patients suggest great caution and individualization of treatment, possibly with the support of the ALBI grade.

Keywords: Benefit; Cirrhosis; Survival; Systemic treatment.

PubMed Disclaimer

Conflict of interest statement

Edoardo G. Giannini has participated in consulting and/or advisory boards for Roche, AstraZeneca, Eisai, MSD. Mario Strazzabosco is an advisor for ENGITIX.

Figures

Fig. 1.
Fig. 1.
a Risk of bias summary: review authors’ judgment about each risk of bias item for each included study. b Risk of bias graph: review authors’ judgment about each risk of bias item presented as percentages across all included studies.
Fig. 2.
Fig. 2.
a Sensitivity analysis of odd ratios for adverse events in Child-Pugh classes. OR, odds ratio.
Fig. 3.
Fig. 3.
Forest plots of the sensitivity analysis of (a) median, (b) 6-month, and (c) 12-month progression-free survival (PFS) in Child-Pugh classes.
Fig. 4.
Fig. 4.
Sensitivity analysis of OR for (a) disease control rate (DCR) and (b) objective response rate (ORR) in Child-Pugh classes.
Fig. 5.
Fig. 5.
Forest plots of the sensitivity analysis of (a) median, (b) 6-month, and (c) 12-month overall survival (OS) in Child-Pugh classes.
See this image and copyright information in PMC

References

    1. Garuti F, Neri A, Avanzato F, Gramenzi A, Rampoldi D, Rucci P, et al. . The changing scenario of hepatocellular carcinoma in Italy: an update. Liver Int. 2021;41(3):585–97. - PubMed
    1. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646–9. - PubMed
    1. Park J-W, Chen M, Colombo M, Roberts LR, Schwartz M, Chen P-J, et al. . Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–66. - PMC - PubMed
    1. Jeon D, Song G-W, Lee HC, Shim JH. Treatment patterns for hepatocellular carcinoma in patients with Child-Pugh class B and their impact on survival: a Korean nationwide registry study. Liver Int. 2022;42(12):2830–42. - PubMed
    1. Talbot T, D’Alessio A, Pinter M, Balcar L, Scheiner B, Marron TU, et al. . Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: an international observational study. Liver Int. 2023;43(3):695–707. - PMC - PubMed